Approved revisions

View list of: Pages whose approved revision is not their latest | Unapproved pages | All pages with an approved revision | Pages with invalid approvals

Showing below up to 50 results in range #151 to #200.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. 14. Molecular mechanisms of cardiovascular damages (revision 1580, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  2. 14. Muscarinic receptor antagonists (revision 1985, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  3. 14. Synthesis of non-essential amino acids (revision 1386, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  4. 14. Table of frequent bilestones (revision 578, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  5. 14. The structure, function and origin of erythrocytes (revision 1226, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  6. 14. Tinnitus (revision 3087, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  7. 14. Urothelial carcinoma of the renal pelvis (revision 4698, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  8. 14A. Motor neuron diseases (revision 2236, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  9. 14B. Diagnosis of multiple sclerosis (+ treatment) (revision 2237, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  10. 15. Breast Cancer (revision 5033, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  11. 15. Causation in epidemiology: association and causation (revision 1079, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  12. 15. Characterize the various leukocytes indicating their origins and functions (revision 4093, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  13. 15. Cochlear implantation (revision 3089, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  14. 15. Disorders of immunoglobulins and paraproteins (revision 4075, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  15. 15. Distributive shock: Causes and hemodynamics (revision 1706, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  16. 15. Effector mechanisms of cell-mediated immune response (revision 1515, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  17. 15. Enzymopathies of amino acid metabolism (revision 1387, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  18. 15. Epidemiology and prevention of breast cancer (revision 1160, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  19. 15. Formation of the fetal membranes and the placenta. Fetal circulation (revision 1655, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  20. 15. Genetically modified organisms (revision 1117, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  21. 15. Hepatocellular carcinoma (revision 4633, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  22. 15. Imaging of the liver and the hepatobiliary system. Imaging techniques, indications, information content. (revision 3384, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  23. 15. Jaundice (revision 1862, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  24. 15. Neuromuscular blocking agents (revision 1987, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  25. 15. Nodular calcified aortic stenosis (revision 4406, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  26. 15. Normal and hypertrophic cardiac muscle (revision 4474, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  27. 15. Pathomechanism and clinicopathological forms of stone formation (revision 236, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  28. 15. Sensation (revision 1585, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  29. 15. Toxoplasma lymphadenitis (revision 4700, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  30. 15. Tumours and tumourlike conditions of the liver (revision 93, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  31. 15A. Trigeminal neuralgia (revision 2238, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  32. 15B. Neuromyelitis optica (Devic-disease) (revision 2239, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  33. 16. Agents acting on the biosynthesis, storage, release and elimination of catecholamines (revision 1991, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  34. 16. Assessment of acute phase proteins, diagnosis and monitoring of sepsis (revision 4083, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  35. 16. Cancer of the oesophagus and the stomach (revision 5041, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  36. 16. Cerebral atrophy (revision 582, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  37. 16. Cholelithiasis (aetiology and complications) and pathology of the extrahepatic biliary tract (revision 94, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  38. 16. Cirrhosis. Causes, mechanisms and consequences. Hepatic cachexia. (revision 1863, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  39. 16. Epidemiological indicators I: indicators of disease frequency and population impact of a disease (revision 1080, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  40. 16. Epidemiology and prevention of prostate and cervix cancer (revision 1161, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  41. 16. Follicular lymphoma (revision 4705, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  42. 16. General characterisation of amyloidosis. Physico-chemical, ultrastructural and histochemical nature of amyloid. Types of amyloid (revision 240, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  43. 16. Imaging of the pancreas and the spleen. Imaging techniques, indications, information content. (revision 3385, approved by 127.0.0.1 on 26 November 2024 at 10:57)
  44. 16. Interaction of environmental and genetical factors in disease development (revision 1118, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  45. 16. Nervous system I (revision 1590, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  46. 16. Neurulation. The structure of the neural tube. Development of the spinal cord (revision 4247, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  47. 16. Organ manifestations of shock (revision 1708, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  48. 16. Origin and function of blood platelets (revision 1228, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  49. 16. Prostatic hyperplasia (revision 4475, approved by 127.0.0.1 on 26 November 2024 at 10:56)
  50. 16. Sleep apnoea (revision 3094, approved by 127.0.0.1 on 26 November 2024 at 10:57)

View ( | ) (20 | 50 | 100 | 250 | 500)